Oral Abstract Schedule

Thursday Oral Abstract Schedule

1:15 - 2:15 pmDr. Amy HeimbergerKEYNOTE PRESENTATION:
Immunobiology and immunotherapy for CNS tumors in man and his best friend
Sponsored by VetDC

2:15 - 2:30 pmDr. Jennifer CarrollHigh intensity focused ultrasound (HIFU) for treatment of subcutaneous
solid tumors in dogs
2:30 - 2:45 pmDr. Giovanna CotoRetrospective analysis of prognostic factors and treatment options for
canine aortic body chemodectomas
2:45 - 3:00 pmDr. Sessaly ReichHER2 protein expression in canine tissues and relevance as an
immunotherapeutic target in canine osteosarcoma
3:00 - 3:30 pmAfternoon Break
3:30 - 3:45 pmDr. Samantha BajorekEvaluation of the purity of compounded chemotherapy drugs:
A comparison between eight compounding pharmacies
3:45 - 4:00 pmDr. Marejka ShaevitzA prospective clinical trial assessing the impact of concurrent administration
of famotidine or omeprazole on the incidence and severity of gastrointestinal
adverse events in dogs with cancer treated with piroxicam
4:00 - 4:15 pmDr. Brittanie PartridgeTemporal characterization of blood-brain barrier disruption and
immunologic responses to HFIRE treatment in the brain
4:15 - 4:30 pmDr. Abbey SadowskiNovel therapy combining KPT-9274 with doxorubicin in dogs
with naive B cell lymphoma
4:30 - 4:45 pmDr. Nathaniel VosStimulation of canine peripheral blood mononuclear cells by
GIFT4 fusion cytokine
4:45 - 5:00 pmDr. Elizabeth WoodTargeted therapy pevonedistat promotes canine melanoma cell death through
DNA replication and senescence


Friday Schedule**

**See Friday concurrent schedule page


Saturday Oral Abstract Schedule

8:00 - 9:00 amDr. Keila TorresKEYNOTE PRESENTATION:
Epigenomic ordering and therapeutic vulnerabilities in peripheral nerve sheath tumors
Sponsored by Elias Animal Health

9:00 - 9:15 amDr. Katherine MegquierAdvancing precision medicine in canine oncology through blood biopsy
9:15 - 9:30 amDr. Heather RoblesDetection of nucleosomes in the blood of canines with cancer and inflammation
9:30 - 9:45 amDr. Yusuke MuraseABCB1-mediated acquired resistance to a dual PI3K/mTOR
inhibitor gedatolisib in canine tumor cell lines
9:45 - 10:00 amDr. Teita IshizakiGenome-wide quantitative DNA methylation analysis in canine malignant
10:00 - 10:30 amResident poster presentations (two minute oral presentation)
Sponsored by Amatheon Animal Health and Boehringer-Ingelheim
10:30 am - 12:00 pmPoster Viewing & Morning Break
2:00 - 2:15 pmDr. Michael ChildressBaseline serum C-reactive protein concentrations are predictive of
survival in dogs with primary nodal diffuse large B-cell lymphoma
2:15 - 2:30 pmMs. Edina KaraiCOX-2 inhibitors to overcome drug resistance on canine lymphoma cell line
2:30 - 2:45 pmDr. Leah AckermanIdentification of the Interleukin-8 (CXCL-8) pathway in feline
squamous cell carcinoma cell lines
2:45 - 3:00 pmDr. Justine CampbellDurability of clinical response to intratumoral tigilanol tiglate in canine MCT
3:00 - 3:30 pmAfternoon Break
3:30 - 3:45 pmDr. Brian FlesnerMulti-modal pain assessment of dogs with primary bone tumors
3:45 - 4:00 pmDr. Heather GardnerThe genomic landscape of canine osteosarcoma implicates DMD
as a therapeutic vulnerability
4:00 - 4:15 pmDr. Marlene HauckGeneration and validation of a gene expression signature for
metastasis in canine soft tissue sarcomas – The necessity of validation studies
4:15 - 4:30 pmDr. Charlie MaitzAs-delivered dosimetry, tolerability, and outcome for intralesional
delivery of IsoPetâ„¢ 90Y-hydrogel in dogs with soft tissue sarcoma
4:30 - 4:45 pmDr. Celina MorimotoThe role of magnetic resonance imaging for radiotherapy planning
of canine meningiomas
4:45 - 5:00 pmDr. Samantha YehResponse to radiotherapy in dogs with primary spinal cord tumors: 20 cases